Compare AUST & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AUST | CMMB |
|---|---|---|
| Founded | 2020 | 2004 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.3M | 10.9M |
| IPO Year | 2021 | 2023 |
| Metric | AUST | CMMB |
|---|---|---|
| Price | $0.53 | $1.22 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 22.8K | ★ 59.0K |
| Earning Date | 11-05-2026 | 11-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $28.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $0.92 |
| 52 Week High | $3.92 | $2.99 |
| Indicator | AUST | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 24.58 | 43.53 |
| Support Level | N/A | $0.99 |
| Resistance Level | $1.43 | $1.91 |
| Average True Range (ATR) | 0.08 | 0.19 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 20.74 |
Austin Gold Corp is focused on the acquisition, exploration, and evaluation of mineral resource properties in the western United States of America (USA). The exploration and development of mineral projects is considered the Company's single business segment. Its projects include Kelly Creek, Lone Mountain, Stockade Mountain, Fourmile Basin, and Miller.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.